 <h1>Zanubrutinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to zanubrutinib: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, zanubrutinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking zanubrutinib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bladder pain</li>
<li>bleeding gums</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>chest pain or tightness</li>
<li>chills</li>
<li>cough</li>
<li>coughing up blood</li>
<li>decreased urine</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>fast, slow, or irregular heartbeat</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>increased thirst</li>
<li>loss of appetite</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nausea or vomiting</li>
<li>nervousness</li>
<li>nosebleeds</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>paralysis</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>prolonged bleeding from cuts</li>
<li>runny or stuffy nose</li>
<li>seizures</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of zanubrutinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
<li>diarrhea</li>
<li>rash</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zanubrutinib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemorrhage (50%), all grades neutropenia (38%), Grade 3 or 4 neutropenia (15%), all grades thrombocytopenia (27%), Grade 3 or 4 thrombocytopenia (10%), all grades leukopenia (25%), all grades anemia (14%)</p>
<p><b>Common</b> (1% to 10%): Grade 3 or 4 anemia, Grade 3 or 4 leukopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Grade 3 or higher infection (23%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (e.g., musculoskeletal pain, musculoskeletal discomfort, myalgia, back pain, arthralgia, arthritis) (14%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Blood uric acid increased (29%), hypokalemia (14%)</p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (28%), bilirubin increased (24%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Second primary malignancies (e.g., nonskin carcinoma)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (39%), pneumonia (15%), cough (14%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (12%)</p>
<p><b>Common</b> (1% to 10%): Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (36%), bruising (14%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (23%), constipation (13%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the names of the BTK inhibitors?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about zanubrutinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: BTK inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zanubrutinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Brukinsa</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Mantle Cell Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zanubrutinib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemorrhage (50%), all grades neutropenia (38%), Grade 3 or 4 neutropenia (15%), all grades thrombocytopenia (27%), Grade 3 or 4 thrombocytopenia (10%), all grades leukopenia (25%), all grades anemia (14%)</p><p><b>Common</b> (1% to 10%): Grade 3 or 4 anemia, Grade 3 or 4 leukopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Grade 3 or higher infection (23%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (e.g., musculoskeletal pain, musculoskeletal discomfort, myalgia, back pain, arthralgia, arthritis) (14%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Blood uric acid increased (29%), hypokalemia (14%)</p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (28%), bilirubin increased (24%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Second primary malignancies (e.g., nonskin carcinoma)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (39%), pneumonia (15%), cough (14%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (12%)</p><p><b>Common</b> (1% to 10%): Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (36%), bruising (14%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (23%), constipation (13%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the names of the BTK inhibitors?</li>
</ul><h2>More about zanubrutinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: BTK inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zanubrutinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Mantle Cell Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>